162 related articles for article (PubMed ID: 36846002)
41. Family history of gastric cancer correlates with decreased expression of HINT1 tumor suppressor gene in gastric mucosa of dyspeptic patients.
Zuk K; Peczek L; Stec-Michalska K; Medrek M; Nawrot B
Oncol Lett; 2012 Jan; 3(1):219-223. PubMed ID: 22740884
[TBL] [Abstract][Full Text] [Related]
42. A pan-cancer analysis of the expression of STAT family genes in tumors and their relationship to the tumor microenvironment.
Zhou M; Zhang P; Da M; Yang R; Ma Y; Zhao J; Ma T; Xia J; Shen G; Chen Y; Chen D
Front Oncol; 2022; 12():925537. PubMed ID: 36176415
[TBL] [Abstract][Full Text] [Related]
43. A Pan-Cancer Analysis of UBE2S in Tumorigenesis, Prognosis, Pathway, Immune Infiltration and Evasion, and Therapy Response from an Immune-Oncology Perspective.
Bao H; Luo Y; Ding G; Fu Z
J Oncol; 2022; 2022():3982539. PubMed ID: 35578600
[TBL] [Abstract][Full Text] [Related]
44. MAN1B1 is associated with poor prognosis and modulates proliferation and apoptosis in bladder cancer.
Wang HF; Wu JH; Gai JW; Yang SQ; Ma QT; Ma HS; Feng Q
Gene; 2018 Dec; 679():314-319. PubMed ID: 30218751
[TBL] [Abstract][Full Text] [Related]
45. A Pan-Cancer Analysis of the Oncogenic Role of
Yang D; Li H; Chen Y; Li C; Ren W; Huang Y
Front Genet; 2022; 13():906174. PubMed ID: 35910232
[No Abstract] [Full Text] [Related]
46. A Pan-Cancer Analysis of SMARCA4 Alterations in Human Cancers.
Peng L; Li J; Wu J; Xu B; Wang Z; Giamas G; Stebbing J; Yu Z
Front Immunol; 2021; 12():762598. PubMed ID: 34675941
[TBL] [Abstract][Full Text] [Related]
47. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
48. Secreted phosphoprotein 1 as a potential prognostic and immunotherapy biomarker in multiple human cancers.
Zeng P; Zhang X; Xiang T; Ling Z; Lin C; Diao H
Bioengineered; 2022 Feb; 13(2):3221-3239. PubMed ID: 35067176
[TBL] [Abstract][Full Text] [Related]
49. Pan-Cancer Analysis Reveals the Multidimensional Expression and Prognostic and Immunologic Roles of
Zhang S; Xiong H; Yang J; Yuan X
Front Mol Biosci; 2021; 8():792154. PubMed ID: 35155565
[TBL] [Abstract][Full Text] [Related]
50. Histidine triad nucleotide-binding protein 1 up-regulates cellular levels of p27KIP1 by targeting ScfSKP2 ubiquitin ligase and Src.
Cen B; Li H; Weinstein IB
J Biol Chem; 2009 Feb; 284(8):5265-76. PubMed ID: 19112177
[TBL] [Abstract][Full Text] [Related]
51. Insights Into the Prognostic Value and Immunological Role of NAAA in Pan-Cancer.
Huang D; Shen J; Zhai L; Chen H; Fei J; Zhu X; Zhou J
Front Immunol; 2021; 12():812713. PubMed ID: 35069601
[TBL] [Abstract][Full Text] [Related]
52. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
Zhang J; Wang K; Hainisayimu T; Li H
Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
[TBL] [Abstract][Full Text] [Related]
53. Integrative Analysis of MALT1 as a Potential Therapeutic Target for Prostate Cancer and its Immunological Role in Pan-Cancer.
Tan H; Xie Y; Zhang X; Wu S; Zhao H; Wu J; Wang W; Lin C
Front Mol Biosci; 2021; 8():714906. PubMed ID: 34926571
[No Abstract] [Full Text] [Related]
54. A systematic analysis of
Jiang Y; Wang X; Li L; He J; Jin Q; Long D; Liu C; Zhou W; Liu K
Front Genet; 2022; 13():926943. PubMed ID: 35991552
[No Abstract] [Full Text] [Related]
55. Systematic Pan-Cancer Analysis Identifies CDK1 as an Immunological and Prognostic Biomarker.
Yang Y; Liu Q; Guo X; Yuan Q; Nian S; Kang P; Xu Z; Li L; Ye Y
J Oncol; 2022; 2022():8115474. PubMed ID: 36090896
[TBL] [Abstract][Full Text] [Related]
56. A pan-cancer analysis of FAT atypical cadherin 4 (FAT4) in human tumors.
Mao W; Zhou J; Hu J; Zhao K; Fu Z; Wang J; Mao K
Front Public Health; 2022; 10():969070. PubMed ID: 36051999
[TBL] [Abstract][Full Text] [Related]
57. Pan-cancer analysis of trophinin-associated protein with potential implications in clinical significance, prognosis, and tumor microenvironment in human cancers.
Li Z; Pu Z; Yang Z; Zhu Y; Deng Y; Li N; Peng F
Front Oncol; 2022; 12():971618. PubMed ID: 36419876
[TBL] [Abstract][Full Text] [Related]
58. Prognostic Implication and Oncogenic Role of PNPO in Pan-Cancer.
Zhang L; Li X; Zhang J; Xu G
Front Cell Dev Biol; 2021; 9():763674. PubMed ID: 35127701
[No Abstract] [Full Text] [Related]
59. Siglec-9, a Putative Immune Checkpoint Marker for Cancer Progression Across Multiple Cancer Types.
Wu Y; Huang W; Xie Y; Wang C; Luo N; Chen Y; Wang L; Cheng Z; Gao Z; Liu S
Front Mol Biosci; 2022; 9():743515. PubMed ID: 35372497
[TBL] [Abstract][Full Text] [Related]
60. CLEC10A can serve as a potential therapeutic target and its level correlates with immune infiltration in breast cancer.
Tang S; Zhang Y; Lin X; Wang H; Yong L; Zhang H; Cai F
Oncol Lett; 2022 Aug; 24(2):285. PubMed ID: 35814828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
